GENOVAC and Inserm co-develop a novel antibody-based approach for prevention and treatment of chronic hepatitis C

FREIBURG, Germany and STRASBOURG, France - Hepatitis C virus (HCV) is a major cause of hepatitis worldwide, currently with 170 million chronic sufferers and future prognoses indicate this number to increase. HCV infects human liver cells and is the leading cause of liver cirrhosis and hepatocellular carcinoma and therefore, a major indication for liver transplantation. Unfortunately, the grafted liver is rapidly re-infected by the virus still present in the patient's body and the disease re-deve...